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Abstract
BACKGROUND: Worldwide gastric cancer (GC) ranks sixth in incidence and second in mortality among all 
malignancies. CDX2 has an essential role in the development and maintenance of intestinal differentiation in the gut 
and ectopic sites such as intestinal metaplasia (IM) of the stomach. SOX2 contributes to the cell lineages normally 
found in the stomach, suggesting contribution in gastric differentiation.
AIM: The aim of the study was to assess the expression of CDX2 and SOX2 in chronic gastritis (CG) lesions 
associated with Helicobacter pylori, IM, or dysplasia as well as in intestinal-type GC.
METHODS: Immunohistochemical staining for CDX2 and SOX2 were applied on archival paraffin blocks from 80 
CG cases, 40 intestinal-type GC cases, and 10 controls. CG cases were either of non-specific inflammation or 
associated with H. pylori infection. GC cases were of intestinal-type only, excluding any other type of GC. Control 
cases were of minimal gastritis, negative for H. pylori, IM, and dysplasia.
RESULTS:  CDX2 expression was correlated with CG associated with H. pylori, IM, and dysplasia as well as with 
more differentiated and less invasive pattern of intestinal-type GC, while SOX2 expression was correlated with CG 
negative for H. pylori and IM as well as with less differentiated and more invasive intestinal-type GC.
CONCLUSION: Both CDX2 and SOX2 could predict the behavior of CG disease over time and plan the suitable line 
of treatment and both proteins could be potential targets for novel therapeutic interventions.
Introduction
According to GLOBOCAN 2018 data, the 
incidence of gastric cancer (GC) ranks sixth and 
mortality ranks second [1]. Although GC prevalence 
has shown a continuous reduction since the last mid-
century, it is still a common malignancy and a frequent 
cause of cancer-related deaths [2]. Both histological 
types of GC: Intestinal and diffuse, present distinct 
morphological, clinical, and epidemiological features 
and are thought to develop from the activation of 
independent molecular mechanisms. Intestinal GC 
develops through a sequence of histological changes, 
including diffuse chronic gastritis (CG), mucosal 
atrophy, intestinal metaplasia (IM), dysplasia, and 
finally invasive carcinoma [3].
Helicobacter pylori are Gram-negative 
spirochetes which infect more than half of the world’s 
population, likely due to water contamination and less 
sanitary living conditions [4]. Infection with H. pylori and 
the resulting chronic inflammation is a major step in the 
initiation and development of almost 90% of new cases 
of GC [5]. The pathogenicity of H. pylori is attributed 
largely to its various virulence components [6]. Chronic 
infection with H. pylori gives rise to IM which is the most 
relevant pre-neoplastic lesion of the stomach affecting 
about 30% of the individuals infected with H. pylori [7].
CDX2 is an intestine-specific homeobox 
transcription factor which is expressed in the intestinal 
epithelial cells from duodenum to the rectum [8] 
and has an essential role in the development and 
maintenance of intestinal differentiation in the gut 
and ectopic sites such as IM of the stomach and 
esophagus [9]. It regulates many cellular processes 
such as cell differentiation, proliferation, cell adhesion, 
migration, and tumor genesis [10]. Its role as a 
prognostic marker in colorectal carcinomas is well 
known, whereas its role in the outcome of gastric 
carcinomas is not yet established [11].
SOX2 is a member of the SOX (SRY-related 
HMG Box) family of transcription factors that play 
diverse roles, starting from orchestrating the mammalian 
embryogenesis [12], later on contributing to the normal 
morphogenesis and homeostasis of the foregut-derived 
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epithelia of the esophagus, lung, and trachea [13]. It has 
been shown, in mice, that SOX2 expression contributes to all 
the cell lineages normally found in the stomach, suggesting 
an important contribution for gastric differentiation [14]. In 
addition, abnormal expression of SOX2 has been observed 
in tumors of the brain, breast, lung, and esophagus. 
However, in the GC context, its role remains puzzling and 
needs further clarification. Furthermore, its interplay with 
CDX2 remains unexplored [15].
This work aims to assess the expression of 
CDX2 and SOX2 as intestinal and gastric differentiation 
markers, respectively, in intestinal-type GCs and 
precancerous conditions, namely, chronic H. pylori 
infection, IM, and dysplasia, to evaluate the role of 
these markers as prognostic indicators of progression 
to gastric carcinoma.
Materials and Methods
Samples
This retrospective study included formalin-
fixed paraffin-embedded blocks of 130 specimens of 
endoscopic and surgically resected gastric lesions, 
divided as 10 blocks for control cases with minimal 
gastritis, negative for H. pylori, IM, and dysplasia; 80 
blocks of cases with CG and 40 intestinal-type GC 
blocks. Blocks were collected from the Pathology 
Department, Theodor Bilharz Research Institute, in a 
period from January 2017 to October 2019.
Specimens of CG cases were obtained as 
endoscopic biopsies, while specimens of GC cases 
were obtained as partial/total gastrectomy specimens.
Table 1: Patients’ characteristics in studied groups
Groups n Gender Age p value
Male n (%) Female n (%) Mean±SD
Control 10 7 (70) 3 (30) 45.20 ± 16.37* p < 0.01
Chronic gastritis 80 44 (55) 36 (45) 51.92 ± 16.43* p < 0.001
Intestinal-type GC 40 26 (65) 14 (35) 60.95 ± 6.86
Total 130 77 (59.2) 53 (40.8)
N: Number, GC: Gastric cancer, *compared to intestinal-type GC.
 Patients’ characteristics were summarized in 
Table 1 and clinicopathological parameters of studied 
cases were shown in Table 2.
Table 2: Clinicopathological parameters
Patients groups n. (%)
Control (10) 10
Chronic gastritis (80) Intensity of inflammation Mild 28 (35)
Moderate 52 (65)
Associated lesions H. pylori infection Present 44 (55)
Absent 36 (45)
IM Present 34 (42.5)
Absent 46 (57.5)
Dysplasia Present 10 (12.5)
Absent 70 (87.5)
Intestinal-type 
GC (40)
Grade of differentiation Low grade 29 (72.5)
High grade 11 (27.5)
Stage of invasion Early stage 27 (67.5)
Advanced stage 13 (32.5)
Vascular invasion (vascular emboli) Present 33 (82.5)
Absent 7 (17.5)
N: Number, H. pylori: Helicobacter pylori, IM: Intestinal metaplasia, GC: Gastric cancer
The protocol of this study was approved by the 
Institutional Review Board of Theodor Bilharz Research 
Institute for the protection of human subject and adopted by 
the 18th world medical assembly, Helsinki, Finland (2013).
Histopathological technique and 
evaluation
Paraffin sections from different gastric lesions 
were cut in 4 µm thickness stained using hematoxylin 
and eosin (H&E) for routine histopathological 
examination and diagnosis. Giemsa stain was used for 
the detection of H. pylori micro-organisms.
CG sections were evaluated for intensity of 
inflammation, presence/absence of H. pylori, IM and 
dysplasia.
Sections of gastric carcinoma were examined 
for tumor grading and staging according to International 
Histological Classification proposed by the World Health 
Organization, 2019. GC is considered as low grade 
(well-differentiated) or high grade (moderately or poorly 
differentiated) and is considered as either early (pT1) 
or advanced (≥pT2) [16]. GCs of antrum were found in 
31/40 cases and that of corpus/funds in 9/40. All were 
of intestinal-type histology.
Immunohistochemical technique
One paraffin-embedded block was selected from 
each case and was cut into 4 µm sections. The sections 
were put in the oven at 60°C for 4 h, deparaffinized in xylene, 
rehydrated in a graded ethanol series, and treated with 3% 
hydrogen peroxide solution for 10 min. Antigen retrieval 
was done by microwaving the tissue in 10 mmol/L citric 
acid buffer for 12 min, then cooling at room temperature 
for 2 h. The sections were incubated with an anti-CDX2 
monoclonal antibody (code no. CMC23531040, Abcam, 
Cambridge, MA, USA) and anti-SOX2 monoclonal antibody 
(code no. ab97959, Abcam, Cambridge, MA, USA), at 
dilution of 1:100 for overnight at 4°C. Sections were then 
washed 3 times for 5 min in phosphate-buffered saline. 
Non-specific staining was blocked with 0.5% casein and 
5% normal serum for 30 min at room temperature. Finally, 
staining was developed with diaminobenzidine substrate 
and sections were counterstained with hematoxylin, 
dehydrated with graded ethanol, and mounted.
For each setting, positive and negative 
controls were routinely used. Negative controls were 
carried out in which phosphate-buffered saline was 
used instead of the primary antibody. Positive control 
slides were pancreatic tissue for CDX2 and squamous 
cell carcinoma of the lung for SOX2.
Assessment of immunostaining
The sections were examined using 
a light microscope (Scope A1, Axio, Zeiss, 
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Germany). Photomicrographs were taken using a 
microscope-camera (AxioCam, MRc5, Zeiss, Germany). 
Two experienced pathologists independently examined 
nuclear CDX2 and SOX2 staining while blind to the 
clinicopathologic data of patients. At least 10 high-
power fields at ×400 were chosen randomly for each 
section. Cases with >5% positive gastric/tumor cells in 
a section were regarded as positive expression. Both 
immunopositivity (number of positive cases) and extent 
of expression (mean percentage of positively stained 
neoplastic cells) were evaluated.
Statistical analysis
Analyses were performed using SPSS 
version 23 (IBM Corp., Armonk, New York, USA). The 
significance of differences in means was calculated 
using One-way ANOVA and the T-test. Chi-square 
and Fischer’s exact tests were used to assess the 
significance of differences in clinicopathological 
characteristics across categories of CDX2 and SOX2 
expression. Differences were considered statistically 
significant whenever the p < 0.05.
Results
In this study, 130 paraffin blocks with gastric 
lesions were enrolled. Seventy-seven patients were male 
(59.2%) and the rest were female (40.8%). The mean 
age for CG patients was 51.92 years and for GC patients 
were 60.95 years; these values were significantly higher 
than that of controls (45.20 years) ( Table 1).
CDX2 immunoreactivity
Our data revealed that CDX2 immunopositivity 
and CDX2 expression were significantly associated 
with male sex in both CG and GC cases (Table 3).
Table 3: Relationship between CDX2 immunostaining and 
gender
Gender in studied groups 
(N.)
CDX2 immunopositivity CDX2 expression  
(% of positive cells)
Positive 
n (%)
Negative 
n (%)
p value Mean ± SD p value
Chronic gastritis (80) 40 (50) 40 (50) 17.88 ± 21.36
Male (44) 35 (79.5) 9 (20.5) p > 0.001 27.72 ± 16.48 p < 0.001
Female (36) 5 (14) 31 (86) 6.94 ± 11.91
Gastric adenocarcinoma (40) 37 (92.5) 3 (7.5) 50.38 ± 25.53
Male (26) 26 (100) 0 p > 0.05 56.07 ± 25.52 p > 0.05
Female (14) 11 (78.6) 3 (21.4) 47.31 ± 18.23
N: Number, GC: Gastric cancer.
CDX2 immunopositivity showed a significant 
difference between studied groups, while it was 
undetectable in controls; 50% of CG cases and 
92.5% of GC cases were CDX2 positive. Moreover, 
CDX2 expression was significantly increased from 0 
in controls to 18.37% in CG to 50.38% in GC cases 
(Table 4) (Figure 1).
Regarding CG cases, CDX2 immunopositivity 
and expression were significantly associated with the 
intensity of inflammation, H. pylori infection, IM, and 
dysplasia (Table 4).
Notably, there was a significant increase in 
CDX2 expression in CG cases with IM (30%) to dysplasia 
(47.5%) then to carcinoma (50.38%) (Table 4).
Regarding intestinal-type GC cases, CDX2 
immunopositivity was higher in low grade and early-
stage cancers as well as cancers negative for vascular 
emboli compared with their counterparts, but these 
relationships did not achieve significant values. On 
the other hand, CDX2 expression was significantly 
associated with low grade and early-stage cancers 
(Table 4).
SOX2 immunoreactivity
Our data revealed that the immunopositivity 
and expression of SOX2 were significantly higher in 
males than in females regarding GC cases (Table 5).
We found SOX2 immunopositivity in 70% of 
control cases in scattered foci of foveolar cells. Only 
22.5% of CG cases were positive for SOX2 compared 
Figure 1: Immunohistochemical expression of CDX2. (a) Moderate 
chronic gastritis with Helicobacter pylori, positivity in ~40% of gastric 
cells (×200), (b) Moderate chronic gastritis with intestinal metaplasia, 
positivity in ~ 40% of gastric cells (×200), (c) Moderate chronic 
gastritis with intestinal metaplasia and dysplasia, positivity in ~ 80% 
of gastric cells (×200), (d) Low-grade intestinal-type gastric cancer, 
positivity in ~ 80% of malignant gastric cells (×200), (e) High-grade 
intestinal-type gastric cancer, positivity in ~ 60% of malignant gastric 
cells (200)
a b
dc
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to positivity in 80% intestinal-type GC with a significant 
difference between both groups (Table 6). Furthermore, 
SOX2 expression significantly increased from 11.5% in 
CG to 52.38% in intestinal-type GC (Figure 2).
In CG cases, intensity of inflammation – either 
mild or moderate – did not affect immunoreactivity for 
SOX2. CG with dysplasia significantly showed higher 
SOX2 immunopositivity and expression than in CG 
without dysplasia (Table 6).
Regarding intestinal-type GC cases, SOX2 
immunopositivity was higher in high grade and in 
advanced stage GCs than with low grade and early-
stage cancers, but with no statistically significant 
difference. However, we found that SOX2 expression 
was significantly increased in high grade and 
advanced-stage cancers compared with low grade and 
early-stage cancers. Vascular invasion did not affect 
immunoreactivity for SOX2 (Table 6).
Discussion 
Considering GC as one of the main cancer-
causing deaths and being a disease with multiple 
outcomes that cannot be predicted by clinicopathological 
features alone [17], finding precise prognostic factors 
in patients with GC is an urgent need. Moreover, GC 
represents an example of inflammation-linked cancer. 
The progression of H. pylori-infected CG facilitates the 
development of IM, which has been extensively studied 
as a premalignant condition of gastric carcinoma [18].
In this study, we assess immunoreactivity of 
CDX2 and SOX2 in different gastric lesions according 
to the number of positive cases (immunopositivity) 
and mean percentage of positive gastric and tumor 
cells (expression). CDX2 and SOX2 were considered 
immunopositive when immunoreactivity was observed 
in >5% of gastric/tumor cells, leading to a higher 
prevalence of CDX2 and SOX2 immunopositivity in 
our study (92.5% and 80%, respectively) than that 
Table 4: CDX2 immunostaining in studied groups
Diagnosis (n.) CDX2 immunopositivity CDX2 expression (% of positive cells)
Positive n (%) Negative n (%) p value Mean ± SD p value
Control (10) 0 10 p < 0.01 00 ± 00 p > 0.001
Chronic gastritis (80) 40 (50) 40 (50) 18.37 ± 17.86
Intensity of inflammation Mild (28) 8 (28.6) 20 (71.4) p < 0.01 10.17 ± 8.66 p > 0.01
Moderate (52) 32 (61.5) 20 (38.5) 22.79 ± 19.93
Associated lesions H. pylori infection Present (44) 27 (61.4) 17 (38.6) p < 0.05 23.52 ± 15.27 p > 0.01
Absent (36) 13 (36) 23 (64) 12.08 ± 18.95
IM Present (34) 27 (79.4) 7 (20.6) p < 0.001 30.00 ± 17.71 p > 0.001
Absent (46) 13 (28.3) 33 (71.7) 9.78 ± 12.34
Dysplasia Present (10) 10 (100) 0 p < 0.001 47.50 ± 6.34† p > 0.001
Absent (70) 30 (43) 40 (57) 14.21 ± 14.81
Intestinal-type GC (40) 37(92.5)* 3 (7.5) 50.38 ± 25.53*,‡, §
Grade of differentiation Low grade (29) 28 (96.6) 1 (3.4) p > 0.05 61.38 ± 19.73 p > 0.001
High grade (11) 9 (81.8) 2 (18.2) 21.36 ± 13.25
Stage of invasion Early stage (27) 26 (96.3) 1 (3.7) p > 0.05 60.74 ± 20.12 p > 0.001
Advanced stage (13) 11 (84.6) 2 (15.4) 28.85 ± 22.28
Vascular invasion Present (33) 30 (91) 3 (9) p > 0.05 48.03 ± 27.24 p > 0.05
Absent (7) 7 (100) 0 61.43 ± 10.29
N: Number, H. Pylori: Helicobacter pylori, IM: Intestinal metaplasia, GC: Gastric cancer, *p < 0.001 compared to control and CG, †p < 0.01 compared to IM, ‡p < 0.05 compared to dysplasia, §p < 0.001 compared to IM.
Table 5: Relationship between SOX2 immunostaining and 
gender
Gender in studied  
groups (n.)
SOX2 immunopositivity SOX2 expression (% of 
positive cells)
Positive  
n (%)
Negative 
n (%)
p value Mean ± SD p value
Control (10) 9.00 ± 6.58
Male (7) 4 (57) 3 (43) p < 0.05 10.71 ± 5.35 p < 0.05
Female (3) 3 (100) 0 5.0 ± 8.66
Chronic gastritis (80) 52.38 ± 28.82
Male (44) 10 (22.7) 34 (77.3) p >0.05 13.41 ± 25.78 p < 0.05
Female (36) 8 (22.2) 28 (77.8) 9.17 ± 19.44
Intestinal-type GC (40)
Male (26) 25 (96.2) 1 (3.8) p < 0.001 60.96 ± 16.91 p < 0.01
Female (14) 7 (50) 7 (50) 36.43 ± 39
N: Number; GC: Gastric cancer.
Figure 2: Immunohistochemical expression of SOX2. (a) Mild chronic 
gastritis, positivity in ~ 40% of gastric cells (×200), (b) Moderate 
chronic gastritis with Helicobacter pylori, positivity in ~ 30% of 
gastric cells (×200), (c) Chronic gastritis with H. pylori and intestinal 
metaplasia, positivity in ~ 30% of gastric cells (×200), (d) Low-grade 
intestinal-type gastric cancer, positivity in ~ 40% of malignant gastric 
cells (×200), (e) High-grade intestinal-type gastric cancer, positivity in 
~ 80% of malignant gastric cells (×200)
a b
c d
e
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reported in other studies as Bao et al. [19] (35.1%), 
Fan et al. [20] (~76%), and Harras and Mowafy [21] 
(81.25%) regarding CDX2 immunopositivity, and 
studies by Camilo et al. [22] (52%) and Yang et al. [23] 
(41.7%) regarding SOX2 immunopositivity.
Clinicians encounter sex disparities in 
diagnostic and therapeutic responses. Data in our 
study revealed that male:female ratio was 1.2:1 in CG 
cases and 1.9:1 in GC cases. Furthermore, we found 
an association between male sex and both CDX2 and 
SOX2 expression. This is in line with the findings of Bao 
et al. [19] and Camilo et al. [22].
In our study, the mean age for intestinal-type 
GC cases was of 60.95 years, with male:female ratio 
1.9:1. However, Saha et al. [24], in their study, found a 
median age of 55 years with male:female ratio of 2.7:1. 
In Halder et al. [11] study, the mean age was 51.16 
years with a male:female ratio of 1.63:1.
In the current study, CDX2 was undetectable 
in control cases, this goes with studies of Fan et al. [20] 
and Bao et al. [19], who reported negative CDX2 staining 
in normal gastric mucosa and stromal cells. CDX2 
immunopositivity and expression were sequentially 
increased from CG to intestinal-type GC. This is parallel 
to the fact that GC is one of the inflammation-linked 
cancers [25].
In concordance with Saito et al. [26], who 
reported a relationship between CDX2 expression 
and intensity of inflammation, we found a significant 
association between CDX2 (immunopositivity and 
expression) with a moderate intensity of inflammation 
in CG cases.
In our study, CDX2 immunopositivity was 
significantly higher in H. pylori positive cases than 
negative ones, a finding consistent with previous 
reports which have shown that H. pylori induces 
CDX2 expression in the human stomach before the 
development of IM [9], [27]. Several studies have 
demonstrated that H. pylori infection leads to the 
expression of CDX2 in areas of IM and also in foci 
of non-metaplastic cells [28], [29]. However, other 
studies have demonstrated that CDX2 expression 
is higher in H. pylori-negative patients than positive 
patients [30], [31].
As an intestine-specific transcription factor, 
CDX2 has a key role in regulating the proliferation 
and differentiation of intestinal cells and maintaining 
intestinal phenotypes in the gastric epithelium [19], [32]. 
Consistent with this literature, we found a significantly 
higher CDX2 immunopositivity and expression in CG 
with IM than cases without IM.
Reinforcing the role of CDX2 as a biomarker 
of progression in the preneoplastic stages of gastric 
carcinogenesis, we observed a significant increase in 
CDX2 expression from IM to dysplasia, this matches 
the finding of Camillo et al. [33] that CDX2 is acquired 
de novo in IM and maintained in dysplasia, on the 
contrary, Kim et al. [34] observed a significant reduction 
in CDX2 expression in the foci of gastric epithelial 
dysplasia when compared with the adjacent metaplastic 
gastric mucosa.
We found that all cases of CG associated with 
dysplasia were immunopositive for CDX2. Similarly, 
Rugge et al. [35] reported positive CDX2 expression 
in all their studied dysplastic lesions. Although we 
observed a gradual decrease of CDX2 immunopositivity 
from dysplasia to early GCs to advanced cancers, CDX2 
expression increased from dysplasia to early GC then 
reduced in advanced cancers. In contrast to our results, 
Mizoshita et al. [36] reported a gradual decrease of 
CDX2 expression from dysplasia to early to advance 
GCs. This controversy can be attributed to the small 
number of our dysplastic lesions. Immunopositivity and 
expression of CDX2 between dysplasia and cancer 
were not different. The same finding was reported by 
Kang et al. [32].
Regarding CDX2 expression in GC, we found 
CDX2 immunopositivity in 92.5% of studied GC cases. 
It has been suggested that the intestinal-type gastric 
carcinoma may be transformed from IM [37]. This may 
account for the high positivity of CDX2 in intestinal-
type gastric carcinomas. However, we found lower 
expression in high grade and advanced-stage 
cancers than in low grade and early-stage ones. This 
Table 6: SOX2 Expression in studied groups
Diagnosis (N.) SOX2 immunopositivity SOX2 expression (% of positive cells)
Positive n (%) Negative n (%) p value Mean ± SD p value
Control (10) 7 (70) 3 (30) p < 0.001 9.00 ± 6.58 p > 0.05
Chronic gastritis (80) 18 (22.5) 62 (77.5) 11.50 ± 23.10
Intensity of inflammation Mild (28) 6 (21.4) 22 (78.6) p > 0.05 13.21 ± 26.25 p > 0.05
Moderate (52) 12 (23) 40 (77) 10.58 ± 21.43
Associated lesions H. pylori infection Present (44) 5 (11.4) 39 (88.6) p < 0.01 p > 0.05 p > 0.05
Absent (36) 13 (36) 23 (64) 16.67 ± 24.93
IM Present (34) 6 (17.6) 28 (82.4) p > 0.05 8.53 ± 17.21 p > 0.05
Absent (46) 12 (26) 34 (74) 13.7 ± 26.61
Dysplasia Present (10) 5 (50)† 5 (50) p < 0.05 28 ± 31.2 ‡ p > 0.01
Absent (70) 13 (18.6) 57 (81.4) 9.14 ± 20.95
Intestinal-type GC (40) 32 (80)*§,|| 8 (20) 52.38 ± 28.82*,**
Grade of differentiation Low Grade (29) 22 (76) 7 (24) p > 0.05 44.14 ± 25.85 p > 0.05
High Grade (11) 10 (91) 1 (9) 77.73 ± 28.93
Stage of invasion Early Stage (27) 20 (74.1) 7 (25.9) p > 0.05 42.59 ± 26.11 p > 0.001
Advanced stage (13) 12 (92.3) 1 (7.7) 72.69 ± 23.68
Vascular invasion Present (33) 25 (75.8) 8 (24.2) p > 0.05 51.97 ± 31.74 p > 0.05
Absent (7) 7 (100) 0 54.29 ± 4.50
N: Number, H. pylori: Helicobacter pylori, IM: Intestinal metaplasia, GC: Gastric cancer, †p < 0.05 compared to IM, *p < 0.001 compared to control and CG, §,||p < 0.05 and p < 0.001 compared to dysplasia and IM, respectively, 
‡p < 0.01 compared to IM, **p < 0.05 and p < 0.001 compared to dysplasia and IM, respectively.
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is consistent with previous reports by Satio et al. [25] 
and Wang et al. [38], which stated that CDX2 was 
expressed more at a low grade and early stage of 
gastric carcinogenesis intestinal phenotypic elements 
and could be associated with the shift from gastric to 
intestinal phenotype expression. In a study done by Qin 
et al. [39], a significant negative association between 
expression of CDX2 and stage of GC was detected 
and also they found CDX2 positive patients had longer 
survival than those who were CDX2 negative. Mizoshita 
et al. [40] also reported that CDX2 expression was 
associated with a favorable outcome. Furthermore, 
Roessler et al. [41] indicated that reduction of CDX2 
may represent a marker of tumor progression.
Consistent with Bao et al. [19], we did not find a 
correlation between CDX2 immunopositivity and CDX2 
expression with vascular invasion.
SOX2 can act both as an oncogene and a tumor 
suppressor in different types of cancer, suggesting 
that the role of transcription factors in cancer initiation 
may depend on several factors, including the other 
oncogenic mutations involved in cell transformation and 
the cell type of origin [42]. Although transcription factors 
are not classical drug targets, approaches to SOX2-
targeted therapy are already being addressed in breast 
cancer [43].
In the current study, we found SOX2 
expression in scattered deep gastric glands of control 
cases. This was in agreement with Camilo et al. [33], 
who reported a consistent SOX2 expression in normal 
gastric mucosa, mostly in the neck region. Then, 
SOX2 expression was observed in CG and increased 
significantly in intestinal-type GC cases. These findings 
identified that SOX2 expression was evident in normal 
mucosa and maintained in CG and GC, which reinforce 
its association with gastric differentiation. Our results 
were consistent with previous literature by Basat 
et al. [44] and Hutz et al. [45], who reported significant 
SOX2 overexpression in GC relative to the adjacent 
normal tissues, concluding that SOX2 has a potential 
role on oncogenesis, epithelial to mesenchymal 
transition, tumor progression, and metastasis. 
However, other studies reported downregulated SOX2 
expression in gastric tumor tissue and suggested that 
SOX2 can function as a tumor suppressor by regulating 
the cell cycle and apoptosis [46], [47]. This paradoxical 
role of SOX2 in GC was reported by Carrasco-Garcia 
et al. [48].
We found lower SOX2 immunopositivity and 
expression in CG with H. pylori than in negative ones. 
This goes with the results of Camilo et al. [33] and Yoon 
et al. [49], who stated that SOX2 expression is strongly 
downregulated by H. pylori and attributed this finding 
to H. pylori CagA protein, which induces decreasing in 
SOX2 expression and increasing CDX2 expression.
In agreement with Tsukamoto et al. [50], we 
detected lower SOX2 expression in CG with IM than 
those without. SOX2 and CDX2 are inversely expressed 
in IM, this is explained as SOX2 was suggested as a 
CDX2 repressor since down-regulating its levels led to 
upregulation of CDX2 expression [51].
We observed a significant increase in SOX2 
expression from IM to dysplasia to intestinal-type 
GC. These results indicated a link between these 
lesions based on the profile of SOX2 expression. This 
observation supported by findings that IM is a lesion that 
is difficult to reverse or is even a “point of no return” [52].
Our study revealed a significant increase in 
SOX2 immunopositivity and expression from IM to 
dysplasia; however, Camilo et al. [33] showed reverse 
results. Furthermore, we found a gradual increase 
in SOX2 immunopositivity and expression with 
progression from dysplasia to low-grade GC to high-
grade cancers, suggesting its oncogenic role.
It is well-established that SOX2 is associated 
with gastric differentiation [14]. According to our 
results, this is maintained in GC as we found higher 
SOX2 immunopositivity and expression in high grade 
and advanced intestinal-type GCs compared with 
lower grade and early-stage cancers. This is parallel 
to the results of Basat et al. [44] and Du et al. [53], 
who reported a positive association between SOX2 
expression with poor differentiation and advanced 
tumor stage. On the contrary, Lin et al. [54] stated that 
SOX2 overexpression was associated neither with the 
overall survival nor with the other clinicopathological 
factors including grade and stage, while Yang et al. [23] 
found that SOX2 positive expression was associated 
with shorter survival in patients at early-stage cancers, 
but not at an advanced stage. These conflicting results 
can be attributed to a lack of understanding the role of 
SOX2 as an oncogene or tumor suppressor in GC.
In accordance with Camilo et al. [22] and Basat 
et al. [44], we found no significant association between 
vascular invasion and SOX2 immunoreactivity; 
however, Du et al. [53] detected a positive correlation 
between high SOX2 expression with vascular invasion.
SOX2 expression is inversely correlated with 
CDX2 expression (p = 0.004, r = –0.242). CDX2 was 
associated with CG with H. pylori and with IM as well 
as intestinal-type GCs with low grade and early stage, 
while SOX2 was associated with CG without H. pylori 
and without IM as well as intestinal-type GCs of high 
grade and advanced stage. These results suggest that 
the progression from normal gastric to IM to intestinal-
type GC occurs with a gain of intestinal differentiation 
and loss of gastric differentiation. These results are in 
line with Camillo et al. [22]; Cobler et al. [55]; and Yoon 
et al. [49], who reported that there was a significant 
inverse correlation between the expression of SOX2 and 
CDX2 in gastric adenocarcinomas, and SOX2+/CDX2− 
profile was associated with a poorer prognosis. Different 
studies with mice models suggest that CDX2 negatively 
regulates SOX2 and also the reverse [56], [57].
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The present study had several advantages 
compared to previous studies. First, it investigated 
CDX2 and SOX2 in CG and GC lesions, while most of 
the previous studies covered only one of both lesions. 
Second, it evaluated the effect of H. pylori infection 
and IM associated with CG on the expression of CDX2 
and SOX2. However, the study had limitations by the 
relatively small number of studied cases.
Conclusion
The inverse relationship between CDX2 
and SOX2 suggests that both could be markers for 
evaluating GC progression and outcome. This study 
revealed that CDX2 positive expression was related to 
CG associated with H. pylori infection, IM, dysplasia, 
as well as to more differentiated and less invasive 
pattern of intestinal-type GC, while SOX2 positive 
expression was related to CG without H. pylori infection 
or IM as well as to less differentiated and more invasive 
intestinal-type GC. Hence, both could predict how CG 
disease will behave over time and plan a suitable line 
of treatment and could be potential targets for novel 
therapeutic interventions.
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